Evaluation of Liposome-Encapsulated Hemoglobin/LR16 Formulation as a Potential Blood Substitute.
Abstract
Reducing the oxygen affinity of liposome-encapsulated hemoglobin (LEH) to a physiologically useful range is a key step in the development of an LEH product that may potentially be used as a blood replacement fluid. Our approach to this challenge is a pharmacological one, that being the development of drug molecules capable of lowering the oxygen affinity of purified hemoglobin. In our initial proposal, we presented data which demonstrated the ability of the phenylureido-substituted phenoxyisobutyric acid compound (LR16) to effectively modulate the oxygen affinity of purified human hemoglobin microencapsulated in lipid vesicles. For the surrogate blood application, LR16 appears to be of greater utility than hemoglobin's natural effector molecule 2, 3-bisphosphoglycerate (DPG) because the latter compound undergoes fairly rapid hydrolysis during storage, thereby adversely affecting the integrity of the product.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 1990
- Accession Number
- ADA229090
Entities
People
- Thomas G. Burke
Organizations
- City of Hope National Medical Center